LRRC15 Protein (AA 22-538) (His tag,AVI tag,Biotin)

Produktnummer ABIN7013190

Produktdetails

Target: LRRC15 (Leucine Rich Repeat Containing 15 (LRRC15))

Protein-Typ: Recombinant

Proteineigenschaft: AA 22-538

Spezies: Human

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses LRRC15 Protein ist gelabelt mit His tag,AVI tag,Biotin.

Verwendungszweck: Biotinylated Human LRRC15 / LIB Protein, His,Avitag™ (MALS verified)

Spezifität: Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Reinheit: >95 % as determined by SDS-PAGE.

Endotoxin-Niveau: Less than 1.0 EU per μg by the LAL method.

Anwendungsinformationen

Kommentare:

Ready-to-use Avitag™ biotinylated protein:
The product is exclusively produced using the Avitag™ technology. Briefly, a unique 15 amino acid peptide, the Avi tag, is introduced into the recombinant protein during expression vector construction. The single lysine residue in the Avi tag is enzymatically biotinylated by the E. Coli biotin ligase BirA.

This single-point enzymatic labeling technique brings many advantages for commonly used binding assays. The biotinylation happens on the lysine residue of Avi tag, and therefore does NOT interfere with the target protein's natural binding activities. In addition, when immobilized on an avidin-coated surface, the protein orientation is uniform because the position of the Avi tag in the protein is precisely controlled.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: PBS, pH 7.4

Lagerung: -20 °C

Antigendetails

Target: LRRC15 (Leucine Rich Repeat Containing 15 (LRRC15))

Andere Bezeichnung: LRRC15 (LRRC15 Produkte)

Hintergrund: LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody-drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

Molekulargewicht: 61.5 kDa

NCBI Accession: NP_570843